Diabetes careAug 21, 2026

Heart and Metabolism Effects of Drugs Targeting Both GLP-1 and Glucagon Receptors

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Aug 22, 2026

Abstract

Dual GLP-1R and glucagon receptor (GCGR) agonists may modify cardiometabolic risk factors.

Selective GLP-1R agonists are associated with reduced body weight.
Improvement in cardiometabolic risk factors is linked to GLP-1R agonism.
The effects of combining GLP-1R and GCGR agonism on these risk factors remain unclear.
Assessment was conducted through randomized controlled trials.

Simplified

Selective glucagon-like protein 1 receptor (GLP-1R) agonists reduce body weight and improve cardiometabolic risk factors. However, whether dual GLP-1R and glucagon receptor (GCGR) agonism modifies these cardiometabolic effects remains unclear. Here, we assessed the effects of dual GLP-1R/GCGR agonists on cardiometabolic risk factors across randomized controlled trials.

Full Text

Full text is available at the source.

View Full Text ↗

Heart and Metabolism Effects of Drugs Targeting Both GLP-1 and Glucagon Receptors

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief